Phase II study of etoposide and alpha-interferon in patients with advanced measurable colorectal carcinoma

Jaffer A. Ajani, James L. Abbruzzese, Avi B. Markowitz, Yehuda Z. Patt, Karen Daugherty

    Research output: Contribution to journalArticle

    1 Scopus citations

    Abstract

    Based on encouraging in vitro and in vivo data, 14 consecutive patients with measurable metastatic previously untreated colorectal carcinoma were treated with a combination of intravenous etoposide and subcutaneous alpha-interferon. Etoposide was given at 60 mg/m2 intravenously on days 1-5 and alpha-interferon at 5 million units/m2 subcutaneously on days 1-5; courses were repeated every 21 days. All 14 patients were evaluable for response and toxicity. None of the patients achieved a complete or partial remission. Toxicity of this combination was moderate. Our data suggest that this combination is ineffective against colorectal carcinoma.

    Original languageEnglish (US)
    Pages (from-to)67-69
    Number of pages3
    JournalInvestigational New Drugs
    Volume11
    Issue number1
    DOIs
    StatePublished - Feb 1 1993

    Keywords

    • alpha-interferon
    • colorectal carcinoma
    • etoposide

    ASJC Scopus subject areas

    • Oncology
    • Pharmacology
    • Pharmacology (medical)

    Fingerprint Dive into the research topics of 'Phase II study of etoposide and alpha-interferon in patients with advanced measurable colorectal carcinoma'. Together they form a unique fingerprint.

  • Cite this